CYCN — Cyclerion Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1755237 ·
Last close
$3.20
Market Cap
$13.86M
52W High
$8.48
52W Low
$1.27
ADV30
110,650
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,209,000 | -3,177,000 | 8,505,000 | 2,823,000 | 1,714,000 |
| Dec 2025 | 1,025,000 | — | -838,000 | -799,000 | 9,985,000 | 3,240,000 | 900,000 |
| Sep 2025 | 875,000 | — | -1,006,000 | -976,000 | 10,415,000 | 4,568,000 | 877,000 |
| Jun 2025 | 93,000 | — | -1,672,000 | -324,000 | 9,370,000 | 3,006,000 | 800,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,314,000
Investing CF
$0
Financing CF
$3,322,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.26
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-271,020,000
Inventory
—
Receivables
$1,000,000
ST Investments
—
EBIT TTM
$-4,973,000
Pretax Income TTM
$-3,528,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,993,000
EBITDA
—
Free Cash Flow
$-2,589,125
Enterprise Value
$10,947,399
Total Cash
$2,823,000
Total Debt
$0
Shares Out
4,330,314
Trailing EPS
$-1.31
Book Value
$1.60
ROE
-67.8%
ROA
-45.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,074,000 | -4,973,000 | -3,528,000 | 9,985,000 | 900,000 | — | -3,314,000 |
| Dec 2024 | 2,000,000 | -3,628,000 | -3,057,000 | 9,575,000 | 725,000 | — | -4,333,000 |
| Dec 2023 | 0 | -9,647,000 | -5,263,000 | 13,374,000 | 2,086,000 | — | -21,245,000 |
| Dec 2022 | 297,000 | -18,540,000 | -44,078,000 | 18,079,000 | 7,627,000 | — | -40,611,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BLRX | BioLineRx Ltd. | $13.75M | $3.16 | — |
| TOVX | Theriva Biologics, Inc. | $13.63M | $0.30 | — |
| GDTC | CytoMed Therapeutics Ltd | $13.61M | $1.15 | — |
| GTBP | GT Biopharma, Inc. | $14.14M | $0.39 | — |
| HOTH | Hoth Therapeutics, Inc. | $13.55M | $0.71 | — |
News headlines (Yahoo Finance, 1h cache)
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline
2026-04-20 14:15 · Yahoo
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?
2026-04-02 13:15 · Yahoo
Top Midday Gainers
2026-04-01 17:51 · Yahoo
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
2026-04-01 11:05 · Yahoo
CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26
2026-02-23 11:53 · Yahoo
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
2026-02-17 12:00 · Yahoo
CYCN: Engineering a Reset; Initiating Coverage of Cyclerion Therapeutics…
2026-02-02 12:14 · Yahoo
BC-Most Active Stocks
2026-01-06 15:30 · Yahoo
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
2026-01-05 21:01 · Yahoo
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal
2025-12-01 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.